Recent submissions

  • Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. 

    Hastie, KM; Li, H; Bedinger, D; Schendel, SL; Dennison, SM; Li, K; Rayaprolu, V; Yu, X; Mann, C; Zandonatti, M; Diaz Avalos, R; Zyla, D; Buck, T; Hui, S; Shaffer, K; Hariharan, C; Yin, J; Olmedillas, E; Enriquez, A; Parekh, D; Abraha, M; Feeney, E; Horn, GQ; CoVIC-DB team1; Aldon, Y; Ali, H; Aracic, S; Cobb, RR; Federman, RS; Fernandez, JM; Glanville, J; Green, R; Grigoryan, G; Lujan Hernandez, AG; Ho, DD; Huang, K-YA; Ingraham, J; Jiang, W; Kellam, P; Kim, C; Kim, M; Kim, HM; Kong, C; Krebs, SJ; Lan, F; Lang, G; Lee, S; Leung, CL; Liu, J; Lu, Y; MacCamy, A; McGuire, AT; Palser, AL; Rabbitts, TH; Rikhtegaran Tehrani, Z; Sajadi, MM; Sanders, RW; Sato, AK; Schweizer, L; Seo, J; Shen, B; Snitselaar, JL; Stamatatos, L; Tan, Y; Tomic, MT; van Gils, MJ; Youssef, S; Yu, J; Yuan, TZ; Zhang, Q; Peters, B; Tomaras, GD; Germann, T; Saphire, EO
    [Figure: see text].
  • Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours. 

    Stankunaite, R; George, SL; Gallagher, L; Jamal, S; Shaikh, R; Yuan, L; Hughes, D; Proszek, PZ; Carter, P; Pietka, G; Heide, T; James, C; Tari, H; Lynn, C; Jain, N; Portela, LR; Rogers, T; Vaidya, SJ; Chisholm, JC; Carceller, F; Szychot, E; Mandeville, H; Angelini, P; Jesudason, AB; Jackson, M; Marshall, LV; Gatz, SA; Anderson, J; Sottoriva, A; Chesler, L; Hubank, M (2021-12-18)
    <h4>Objective</h4>Clinical diagnostic sequencing of circulating tumour DNA (ctDNA) is well advanced for adult patients, but application to paediatric cancer patients lags behind.<h4>Methods</h4>To address this, we have ...
  • Semi-Quantitative Mass Spectrometry in AML Cells Identifies New Non-Genomic Targets of the EZH2 Methyltransferase. 

    Sbirkov, Y; Kwok, C; Bhamra, A; Thompson, AJ; Gil, V; Zelent, A; Petrie, K (2017-07-05)
    Alterations to the gene encoding the EZH2 (KMT6A) methyltransferase, including both gain-of-function and loss-of-function, have been linked to a variety of haematological malignancies and solid tumours, suggesting a complex, ...
  • The biguanide polyamine analog verlindamycin promotes differentiation in neuroblastoma via induction of antizyme. 

    Urban-Wójciuk, Z; Graham, A; Barker, K; Kwok, C; Sbirkov, Y; Howell, L; Campbell, J; Woster, PM; Poon, E; Petrie, K; Chesler, L (2021-09-14)
    Deregulated polyamine biosynthesis is emerging as a common feature of neuroblastoma and drugs targeting this metabolic pathway such as DFMO are in clinical and preclinical development. The polyamine analog verlindamycin ...
  • Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. 

    Carotenuto, P; Amato, F; Lampis, A; Rae, C; Hedayat, S; Previdi, MC; Zito, D; Raj, M; Guzzardo, V; Sclafani, F; Lanese, A; Parisi, C; Vicentini, C; Said-Huntingford, I; Hahne, JC; Hallsworth, A; Kirkin, V; Young, K; Begum, R; Wotherspoon, A; Kouvelakis, K; Azevedo, SX; Michalarea, V; Upstill-Goddard, R; Rao, S; Watkins, D; Starling, N; Sadanandam, A; Chang, DK; Biankin, AV; Jamieson, NB; Scarpa, A; Cunningham, D; Chau, I; Workman, P; Fassan, M; Valeri, N; Braconi, C (2021-11-18)
    FOLFIRINOX, a combination of chemotherapy drugs (Fluorouracil, Oxaliplatin, Irinotecan -FOI), provides the best clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients. In this study we explore the role of ...
  • Investigating acute cellular responses to elevated APOBEC3B expression 

    McCarthy, C (2021-09-30)
    The cytosine deaminase APOBEC3B (A3B) functions as part of innate immunity by mutating viral DNA and preventing replication. Large-scale genome sequencing studies and examination of expression levels have identified mutations ...
  • Recent Advances in ALK2 Inhibitors. 

    Rooney, L; Jones, C (2021-08-06)
    Activin receptor-like kinase-2 (ALK2) is a type I bone morphogenetic protein (BMP) receptor which has a role in biological processes that control the development of bone, heart, brain, and other tissue. Gain of function ...
  • Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs. 

    Jones, JR; Barber, A; Le Bihan, Y-V; Weinhold, N; Ashby, C; Walker, BA; Wardell, CP; Wang, H; Kaiser, MF; Jackson, GH; Davies, FE; Chopra, R; Morgan, GJ; Pawlyn, C
  • Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma. 

    Carvalho, DM; Richardson, PJ; Olaciregui, N; Stankunaite, R; Lavarino, C; Molinari, V; Corley, EA; Smith, DP; Ruddle, R; Donovan, A; Pal, A; Raynaud, FI; Temelso, S; Mackay, A; Overington, JP; Phelan, A; Sheppard, D; Mackinnon, A; Zebian, B; Al-Sarraj, S; Merve, A; Pryce, J; Grill, J; Hubank, M; Cruz, O; Morales La Madrid, A; Mueller, S; Carcaboso, AM; Carceller, F; Jones, C (2021-09-22)
    Somatic mutations in ACVR1 are found in a quarter of children with diffuse intrinsic pontine glioma (DIPG), however there are no ACVR1 inhibitors licensed for the disease. Using an Artificial Intelligence-based platform ...
  • The molecular pathology of infant gliomas 

    Clarke, M (2021-04-30)
    Infant high grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumours. I have collected 241 cases ...
  • Targeting androgen receptor splicing in lethal prostate cancer 

    Paschalis, A (2021-04-30)
    Over the past decade, androgen receptor (AR) directed therapies such as abiraterone and enzalutamide have become the standard of care for treating advanced prostate cancer, improving both progression-free and overall ...
  • Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. 

    Shern, JF; Selfe, J; Izquierdo, E; Patidar, R; Chou, H-C; Song, YK; Yohe, ME; Sindiri, S; Wei, J; Wen, X; Rudzinski, ER; Barkauskas, DA; Lo, T; Hall, D; Linardic, CM; Hughes, D; Jamal, S; Jenney, M; Chisholm, J; Brown, R; Jones, K; Hicks, B; Angelini, P; George, S; Chesler, L; Hubank, M; Kelsey, A; Gatz, SA; Skapek, SX; Hawkins, DS; Shipley, JM; Khan, J
    Purpose Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent disease remains poor, and beyond PAX-FOXO1 fusion ...
  • Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. 

    Sumanasuriya, S; Seed, G; Parr, H; Christova, R; Pope, L; Bertan, C; Bianchini, D; Rescigno, P; Figueiredo, I; Goodall, J; Fowler, G; Flohr, P; Mehra, N; Neeb, A; Rekowski, J; Eisenberger, M; Sartor, O; Oudard, S; Geffriaud-Ricouard, C; Ozatilgan, A; Chadjaa, M; Macé, S; Lord, C; Baxter, J; Pettitt, S; Lambros, M; Sharp, A; Mateo, J; Carreira, S; Yuan, W; de Bono, JS
    Background Better blood tests to elucidate the behaviour of metastatic castration-resistant prostate cancer (mCRPC) are urgently needed to drive therapeutic decisions. Plasma cell-free DNA (cfDNA) comprises normal and ...
  • Frequency and Prognostic Impact of <i>ALK</i> Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). 

    Bellini, A; Pötschger, U; Bernard, V; Lapouble, E; Baulande, S; Ambros, PF; Auger, N; Beiske, K; Bernkopf, M; Betts, DR; Bhalshankar, J; Bown, N; de Preter, K; Clément, N; Combaret, V; Font de Mora, J; George, SL; Jiménez, I; Jeison, M; Marques, B; Martinsson, T; Mazzocco, K; Morini, M; Mühlethaler-Mottet, A; Noguera, R; Pierron, G; Rossing, M; Taschner-Mandl, S; Van Roy, N; Vicha, A; Chesler, L; Balwierz, W; Castel, V; Elliott, M; Kogner, P; Laureys, G; Luksch, R; Malis, J; Popovic-Beck, M; Ash, S; Delattre, O; Valteau-Couanet, D; Tweddle, DA; Ladenstein, R; Schleiermacher, G (2021-06-11)
    Purpose In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied ALK genetic alterations in high-risk (HR) patients on ...
  • Investigating the phosphinic acid tripeptide mimetic DG013A as a tool compound inhibitor of the M1-aminopeptidase ERAP1. 

    Wilding, B; Pasqua, AE; E A Chessum, N; Pierrat, OA; Hahner, T; Tomlin, K; Shehu, E; Burke, R; Richards, GM; Whitton, B; Arwert, EN; Thapaliya, A; Salimraj, R; van Montfort, R; Skawinska, A; Hayes, A; Raynaud, F; Chopra, R; Jones, K; Newton, G; Cheeseman, MD
    ERAP1 is a zinc-dependent M1-aminopeptidase that trims lipophilic amino acids from the N-terminus of peptides. Owing to its importance in the processing of antigens and regulation of the adaptive immune response, dysregulation ...
  • Precision genomics for prostate cancer patient stratification 

    Seed, G (2020-10-31)
    Introduction Several unmet needs currently persist in advanced prostate cancers. Despite recent discoveries, such as identification of deficient DNA repair pathways as a key driver of prostate tumour development, relatively ...
  • Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead. 

    Shrestha, S; Morcavallo, A; Gorrini, C; Chesler, L
    The constitutive and dysregulated expression of the transcription factor MYCN has a central role in the pathogenesis of the paediatric brain tumour medulloblastoma, with an increased expression of this oncogene correlating ...
  • Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis. 

    Herranz, C; Mateo, F; Baiges, A; Ruiz de Garibay, G; Junza, A; Johnson, SR; Miller, S; García, N; Capellades, J; Gómez, A; Vidal, A; Palomero, L; Espín, R; Extremera, AI; Blommaert, E; Revilla-López, E; Saez, B; Gómez-Ollés, S; Ancochea, J; Valenzuela, C; Alonso, T; Ussetti, P; Laporta, R; Xaubet, A; Rodríguez-Portal, JA; Montes-Worboys, A; Machahua, C; Bordas, J; Menendez, JA; Cruzado, JM; Guiteras, R; Bontoux, C; La Motta, C; Noguera-Castells, A; Mancino, M; Lastra, E; Rigo-Bonnin, R; Perales, JC; Viñals, F; Lahiguera, A; Zhang, X; Cuadras, D; van Moorsel, CHM; van der Vis, JJ; Quanjel, MJR; Filippakis, H; Hakem, R; Gorrini, C; Ferrer, M; Ugun-Klusek, A; Billett, E; Radzikowska, E; Casanova, Á; Molina-Molina, M; Roman, A; Yanes, O; Pujana, MA (2021-08-11)
    Inhibition of mTOR is the standard of care for lymphangioleiomyomatosis (LAM). However, this therapy has variable tolerability and some patients show progressive decline of lung function despite treatment. LAM diagnosis ...
  • Fragment-based discovery of HSP70 inhibitors 

    O'Connor, S (2021-01-31)
    Heat Shock Protein 70s (HSP70s) are key molecular chaperones that are overexpressed in many cancers and are often associated with metastasis and poor prognosis. Dual silencing of two isoforms, HSP72 and HSC70, using siRNA ...
  • Characterizing the metabolic fate of (2S, 4R)-4-[18F]fluoroglutamine and its applications in cancer imaging and treatment response monitoring 

    Nguyen, N (2021-01-31)
    Glutaminolysis is a crucial pathway to provide the nitrogen source in addition to the carbon source from the glycolysis pathway for proliferating cells. (2S, 4R)-4-[18F]fluoroglutamine (4-[18F]fluoroglutamine) is potentially ...

View more